UCSF Helen Diller Family Comprehensive Cancer Center | Strategic Alliance Partners

May 29, 2018

Chloe E. Atreya, MD, PhD, assistant clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses maintenance therapy for patients with colorectal cancer.

May 17, 2018

Jeffrey Wolf, MD, emphasizes the importance of identifying risk when diagnosing patients with multiple myeloma.

April 25, 2018

Chloe E. Atreya, MD, PhD, assistant clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses questions regarding sidedness in colorectal cancer.

April 20, 2018

Jeffrey Wolf, MD, clinical professor, Department of Medicine, director, Myeloma Program, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the treatment approach for patients with high-risk multiple myeloma.

April 11, 2018

Andrew Ko, MD, discusses how the approval of pembrolizumab has impacted patients with positive PD-L1 expression and how clinical trials that have reshaped the standard of care in patients with gastric and GEJ cancers.

April 11, 2018

R. Kate Kelley, MD, discusses the incidence of and risk factors for HCC, and emphasizes the sequence of clinical trials that characterized the field in 2017.

April 10, 2018

Katherine Van Loon, MD, gastrointestinal cancer specialist, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the management of rectal cancer.

March 23, 2018

Chloe E. Atreya, MD, PhD, discusses the latest treatment advances in mCRC, including tumor sidedness and emerging immunotherapy strategies.

March 22, 2018

John Gordan, MD, PhD, assistant professor, Division of Hematology/Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses how the adoption of molecular diagnostics has helped further treatment efforts in biliary tract cancers.

March 21, 2018

Eric A. Collisson, MD, discusses ongoing efforts to advance precision medicine in GI malignancies to improve the standard of care.

March 21, 2018

Katherine Van Loon, MD, gastrointestinal cancer specialist, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the design of the multicenter PROSPECT trial.

March 21, 2018

John Gordan, MD, PhD, discusses the challenges of treating patients with biliary tract cancers and novel therapies in development.

March 20, 2018

R. Kate Kelley, MD, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the rising incidence of hepatocellular carcinoma.

March 20, 2018

Margaret A. Tempero, MD, director, University of California, San Francisco (UCSF) Pancreas Center, professor of medicine, Division of Hematology and Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the interest in the pegylated hyaluronidase agent, PEGPH20, and clinical trials exploring other emerging agents in pancreatic cancer.

March 19, 2018

Aaron Logan, MD, PhD, assistant professor of clinical medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses acalabrutinib (Calquence) in chronic lymphocytic leukemia.

March 17, 2018

Andrew Ko, MD, professor, Department of Medicine, University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses exciting data from the 2018 Gastrointestinal Cancers Symposium.

March 15, 2018

R. Kate Kelley, MD, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the clinical impact of REFLECT and CELESTIAL in hepatocellular carcinoma (HCC).

March 15, 2018

Eric A. Collisson, MD, associate professor, Department of Medicine, University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses the focus of clinical trial research and genetic testing in gastrointestinal (GI) cancers.

March 15, 2018

Sara A. Hurvitz, MD, director of the Breast Oncology Program at the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, discusses de-escalation in HER2-positive breast cancer.

March 14, 2018

Chloe E. Atreya, MD, PhD, assistant clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the molecular subgroups in metastatic colorectal cancer (mCRC) and viable treatment options for patients with microsatellite instability (MSI)-high and BRAF-mutated cancers.